All-age survival estimates were standardised to the marginal distribution of young people with leukaemia included in the analysis.ġ64 563 young people were included in this analysis: 121 328 (73♷%) children, 22 963 (14♰%) adolescents, and 20 272 (12♳%) young adults. To control for background mortality, we used life tables by country or region, single year of age, single calendar year and sex, and, where possible, by race or ethnicity. We estimated 5-year net survival by age and morphology, with 95% CIs, using the non-parametric Pohar-Perme estimator. We categorised leukaemia subtypes according to the International Classification of Childhood Cancer (ICCC-3), updated with International Classification of Diseases for Oncology, third edition (ICD-O-3) codes. We grouped patients by age as children (0-14 years), adolescents (15-19 years), and young adults (20-24 years). We analysed data from 258 population-based cancer registries in 61 countries participating in CONCORD-3 that submitted data on patients diagnosed with leukaemia. Here, we aimed to examine worldwide trends in survival from leukaemia, by age and morphology, in young patients (aged 0-24 years). In CONCORD-3, we analysed data for children (aged 0-14 years) and adults (aged 15-99 years) diagnosed with a haematological malignancy during 2000-14 in 61 countries. Leukaemias comprise a heterogenous group of haematological malignancies.
0 Comments
Leave a Reply. |